Cost & Insurance

How much do GLP-1 medications cost in 2026? Wegovy, Zepbound, Ozempic, Mounjaro & Foundayo range from $25 to $1,350/month. With insurance + savings card: $25/mo. Without insurance: $146/mo compounded sema (Yucca Health), $149/mo Foundayo pill, $299 to 449/mo brand injectable (LillyDirect, NovoCare). Medicare: $50/mo, live as of July 2026. Prices verified July 2026 across 53 providers.

Updated July 2026: Medicare Part D now covers Foundayo, Wegovy, and Zepbound for weight loss (live since July 1, 2026) via the Medicare GLP-1 Bridge program. Flat $50/month copay. About 3.8 million Part D enrollees are eligible (KFF, June 2026). Both oral pills (Foundayo and Wegovy tablet) are covered. Runs through Dec 31, 2027 (BALANCE Model Part D launch delayed indefinitely as of April 2026; Bridge extended to fill the gap).

GLP-1 medications like Ozempic and Wegovy can help PCOS because the syndrome is driven by insulin resistance, and these drugs improve insulin sensitivity, drive weight loss, and in trials restored menstrual regularity and raised natural-pregnancy rates. But here is the catch almost no one explains: PCOS by itself is NOT an FDA-approved reason to prescribe any GLP-1, so insurance and brand savings cards hinge on your BMI and comorbidities, not your PCOS diagnosis. This guide covers the trial signal, why insurance denies PCOS-only requests, the BMI rules behind savings cards, and the cheaper cash-pay paths if you do not qualify.

FDA resolved the semaglutide shortage on February 21, 2025 and ended temporary shortage-based enforcement discretion on April 22 for 503A pharmacies and May 22 for 503B facilities. This guide separates those dates from FDA's pending 503B bulk-list proposal and compares paths to discuss with a prescriber.

Updated June 11, 2026: CMS released the official prior authorization request form (cms.gov/glp-1-bridge.pdf, June 8) revealing a key eligibility nuance, beneficiaries with OSA, MASH, T2D, or established CVD are NOT eligible for the Bridge (they route through regular Part D instead). The Bridge is for weight-management-only patients. Four drugs covered at a $50/month flat copay: Foundayo, Wegovy injection, Wegovy oral tablet, and Zepbound KwikPen. Prior auth via Humana/LI NET; requests not processed before July 1. Complete enrollment guide.

Verified August 2026: Tirzepatide prices include $149/mo via Gala on a yearly microdose plan ($169/mo for 3 months), $299/mo via LillyDirect (brand Zepbound 2.5mg vial), $399 for the 5mg vial, $449 for 7.5mg and higher doses when refill conditions are met, $25/mo with an eligible Zepbound savings card, or $1,086/mo retail list price. Full price breakdown with 54 tracked providers.

Tirzepatide's shortage was resolved in October 2024 and shortage-based enforcement discretion ended in early 2025. This guide compares advertised compounded prices with brand Zepbound and explains why legality, formulation, and safety cannot be inferred from availability alone.

Verified July 2026: Zepbound savings card cuts copay to $25/fill ($1,300 max annual savings) with commercial insurance. Mounjaro savings card offers $25 copay for T2D. Both expire Dec 31, 2026. Activate in 2 minutes at zepbound.lilly.com/savings. Full eligibility + backup options.